期刊文献+

干扰素及其聚乙二醇化修饰产物的概述 被引量:1

Overview of Interferons and PEGylated Products
原文传递
导出
摘要 干扰素是一类由不同细胞产生的可溶性糖蛋白,并且具有抗病毒,抗肿瘤和免疫调节功能。目前,干扰素已被用于治疗多种疾病,包括毛细胞白血病、乙型肝炎、丙型肝炎以及其他治疗领域。然而,这种治疗的缺点是干扰素在血液中的短半衰期以及快速被清除。近年来,有资料已证明聚乙二醇(PEG)共轭结合生物分子比其相应的未修饰分子表现出优越的临床应用。然而,虽然蛋白共轭连接聚乙二醇能够延长它们在血液中的半衰期,但是通常会导致生物学和药理学活性的急剧降低甚至活性丧失。在此,对干扰素及其聚乙二醇修饰产物的药理学、药代动力学以及药效进行对比概述。 Interferons are a family of soluble glycoproteins produced by different cells and exhibit antiviral, antitumor and immunomodulation functions. At present they have been used to treat many diseases including hairy-cell leukemia and hepatitis B and C and have been applied to other therapeutic areas. A drawback to the therapy however, is the short serum half-life and rapid clearance of the interferon protein. In recent years, polyethylene glycol (PEG) conjugated biomolecules have been shown to exhibit superior clinically useful properties than their corresponding unmodified parent molecules. However, while the covalent attachment of PEG chains to proteins prolongs their lifetime in vivo, it often results in a dramatic reduction or even loss of biological and pharmacological activities. Herein the pharmacology, pharmacokinetics and pharmacodynamics of interferon and its PEGylated products were compared.
出处 《现代生物医学进展》 CAS 2013年第3期587-589,共3页 Progress in Modern Biomedicine
关键词 干扰素 聚乙二醇 药理学 药代动力学 药效 Interferon Polyethylene Pharmacology Pharmacokinetics Pharmacodynamics
  • 相关文献

参考文献17

  • 1Joerg-Patrick StfJ bgen. Interferon alpha and neuromuscular disorders [J]. Journal ofneuroimmunology,2008,207(1):3-17.
  • 2丁宁玲,朱翔,王勇平.拉米夫定联合干扰素治疗慢性乙型肝炎的疗效观察[J].中国医药导报,2010,7(28):47-48. 被引量:7
  • 3张文杰,李朝霞,田淑菊,毛维武,龚晏萱,屈延.干扰素α治疗慢性丙型肝炎干扰素中和抗体的产生及其对抗病毒治疗疗效的影响[J].临床肝胆病杂志,2010,26(1):27-30. 被引量:10
  • 4周志明.慢性乙肝的干扰素治疗效果和不良反应[J].中国民族民间医药,2010,19(17):89-90. 被引量:5
  • 5Loquai C, Schmidtmann I, Beutel M, et al. Quality of life in melanoma patients during adjuvant treatment with pegylated interferon-alpha 2b: patients' and doctors' views[J]. European journal of dermatology,2011 ,21(6):976-984.
  • 6Welker MW, Zeuzern S. Occult Hepatitis C: How Convincing Are the Current Data? [J]. Hepatology,2009,49(2):665-675.
  • 7Berenguer, Ortiz-Canto C, Jose Abellan J, et al. Hepatitis C virus viral kinetics during alpha-2a or alpha-2b pegylated interferon plus ribavi- rin therapy in liver transplant recipients with different immunosupp- ression regimes [J]. Journal of clinical virology,2012,53(3):231-238.
  • 8Glue P, Fang JW, Rouzier PR, et al. Pegylated interferon alpha2b: pharmacokineties, pharmacodynamics, safety, and preliminary effica- cy data. hepatitis C intervention therapy group [J]. Clin Pharmacol Ther,2000,68(5):556-567.
  • 9吴稷.蛋白质的PEG化[J].生物工程进展,1995,15(4):48-51. 被引量:7
  • 10Algranati NE, Sy S, Modi M. A branched methoxy 40 KDA polye- thylene glycol (PEG) moiety optimizes the pharrnacokinetics (PK) of peginter-feron alpha-2A (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC) [C]. Hepatology,1999,30(4): 190A.

二级参考文献81

共引文献40

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部